

Surgical treatment of T3 prostate cancer

Olof Akre, professor of cancer surgery, Karolinska Institutet



**Karolinska
Institutet**


KAROLINSKA
Universitetssjukhuset

Conflicts of interest


**I HAVE NO POTENTIAL CONFLICT OF INTEREST
TO REPORT**

SPCG-4 (Holmberg, N Engl J Med, 2024)

- 30-years of follow up
- 47% pT3 (surgery arm)
- 5% PSA detected
- PC-specific mortality:
- RR 0.52 (0.40-0.67)
- Overall mortality:
- RR 0.74 (0.64-0.87)
- 15% bidirectional contamination
- Absolute Risk Diff 17%
- = NNT 7




PIVOT trial (Wilt TJ, NEJM 2017)



SPCG-7 (Fosså et al Eur Urol 2016)

80% cT3

20% cT2 PSA>20




Efficacy, SPCG-4 vs SPCG-7

SPCG-4 (at 13.4 yrs)	
Rel risk	0.56 (0.41-0.77)
Abs risk diff	11% (4.5-17.5%)
NNT	8

SPCG-7 (12.2 years)	
0.42 (0.31-0.56)	
16.9 % (10.2-23.5%)	
5.9	

The ProtecT trial – 15 years median follow up (Hamdy et al. N Engl J Med 2023)

- Accrual 1999 to 2009
- 77% Grade Group 1
- 65% low risk
- Most PC deaths in the low-risk group



SPCG-15: Inclusion criteria (n=1 200)


- Age ≤ 75 years
- T3 (-T4)
- ISUP ≥ 2
- M0
- Nodes < 1.5 cm
- PSA < 100 ng/mL

- Arm A: RP + ePLND (+ postop radiotherapy according to clinical guidelines)

- Arm B: RT + neoadjuvant endocrine treatment
 - 6 mo Max androgen block + 18 mo of antiandrogen or LHRH
 - RT regimens
 - External 2 Gy to 78 Gy, or 2,5 Gy to 72,5 Gy)
 - External + Brachy (2*10 Gy or 1*14,5-15 Gy)

- Endpoints
 1. Primary: PC-specific survival
 2. Secondary
 1. Metastasis-free survival
 2. Functional outcome (QoL)

Cumulative inclusion by March 16th 2026 (current # 1143)



The population under study (Gongora et al. Eur Urol Open Science 2022)

Table 3 – Pathology data from the surgical specimen

Postoperative data	Prostatectomy (%)
Number of patients	301 (100)
T stage (pT)	
T2	47 (16)
T3a	107 (36)
T3b	118 (39)
T4	2 (1)
Missing	27 (9)
ISUP grade	
Grade group 1	2 (1)
Grade group 2	62 (21)
Grade group 3	106 (35)
Grade group 4	22 (7)
Grade group 5	82 (27)
Missing	27 (9)
Lymph nodes ^a	
Lymph node status	
Positive	111 (37)
Negative	153 (51)
Missing	37 (12)
No. of positive lymph nodes	
0 lymph nodes	153 (51)
1–3 lymph nodes	88 (29)
>3 lymph nodes	24 (8)
Missing	36 (12)
ISUP = International Society of Urological Pathology.	
^a Seventy-nine patients had both pT3b and positive lymph node status.	

SPCG-15 Organisation

- Sweden
 - Johan Stranne (uro)
 - Camilla Thellenberg Karlsson (onc)
 - Eva Johansson (quality-of-life)
 - PH Vincent (biobanking)
 - Fredrik Jäderling (radiology)
- Norway
 - Bjørn Brennhovd (uro)
 - Wolfgang Lilleby (onc)
- Finland
 - Antti Rannikko (uro)
 - Lauri Mäkelä (onc)
 - Tuomas Mirtti (pathol)
- Denmark
 - Klaus Brasso (uro)
 - Peter Meidahl Petersen (onc)
- Coordinating PI: Olof Akre (Swe)
- Coordinating project managers: Réka Conrad and PH Vincent (Swe)